ArticleLancet (London, England)2021
Anticoagulation in COVID-19: reaction to the ACTION trial.
Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis.Clinical pharmacology and therapeutics · 2022Pooled it
- Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.Journal of thrombosis and haemostasis : JTH · 2021Trial
- Clinical Disease Characteristics and Treatment Trajectories Associated with Mortality among COVID-19 Patients in Punjab, Pakistan.Healthcare (Basel, Switzerland) · 2023Article
- "Thromboinflammation in COVID-19: can α2-macroglobulin help to control the fire?": Comment from Seitz et al.Journal of thrombosis and haemostasis : JTH · 2023Article
- Disseminated intravascular coagulation complicating mild or asymptomatic maternal COVID-19.AJOG global reports · 2022Article
- Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.World journal of experimental medicine · 2022Review
- Analysis of Risk Factors of Soft Tissue Bleeding in COVID-19 Patients: A Point of View After Two Years of Pandemic.Journal of clinical medicine research · 2022Article
- Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?European journal of internal medicine · 2022Article
- Studying the coagulopathy of COVID-19.Lancet (London, England) · 2022Article
- Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19.Biomolecules · 2022Review
- Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort study.Journal of thrombosis and haemostasis : JTH · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.